Rationale: Noninvasive diagnostic multiplex molecular tests may enable the early identification and treatment of viral infections in critically ill immunocompromised patients.
Among patients with hematologic malignancies (HM), up to 40% experience acute respiratory failure (ARF), for which the risk factors include prolonged neutropenia, complex immune deficiencies, and drug-related pulmonary toxicity (1) (2) (3) (4) (5) . The causes of lung disease vary with the nature of underlying malignancy, level of immunosuppression, and treatment intensity. Early identification of the cause of ARF is associated with improved outcomes (6) (7) (8) . Current diagnostic strategies combine semi-invasive tests (fiberoptic bronchoscopy with BAL, minimally invasive computed tomography-guided biopsies) with noninvasive PCR assays on sputum, nasopharyngeal aspirates, and nasal swabs. This combined strategy is expected to identify the cause in about 80% of patients (9) (10) (11) . Hospital mortality, which can reach 50%, is highest when the cause of ARF remains unknown (8, (12) (13) (14) .
Whereas up to 40% of patients with HM have one or more viruses detected in their respiratory samples, viruses, mainly diagnosed with the collection of upper respiratory tract samples, are much less considered than other pathogens, such as bacteria or Aspergillus, as likely cause of ARF (15) (16) (17) (18) . A positive virus PCR test on nasopharyngeal aspirates or nasal swabs may reflect either upper or lower respiratory tract infection, the clinical consequences of which can differ substantially (16, 17) . However, a positive test may also indicate asymptomatic carriage, perhaps with an increased viral burden because of worsening immunosuppression, and with or without an impact on mucosal function and/or the local flora (18) . When the virus is clinically relevant, as seen during H1N1 epidemics, its rapid detection can help to identify patients at risk for respiratory deterioration, determine that isolation and preventive measures are needed, and guide early antiviral therapy (19, 20) .
Multiplex assays on BAL fluid or nasal secretions are effective in detecting a wide range of pathogens (21) (22) (23) , including several viruses known to cause pneumonia (e.g., influenza virus, respiratory syncytial virus [RSV] , parainfluenza virus [PIV], human metapneumovirus [hMPV] ) and others whose potential for causing lower respiratory tract disease is unclear (e.g., rhinovirus, coronavirus) (24, 25) . Thus, whether the detection of viruses in respiratory samples has diagnostic, therapeutic, and/or prognostic relevance is unclear.
The objective of this study was to assess the clinical relevance of a positive PCR assay for viruses on respiratory samples of critically ill hematology patients with or without ARF. We retrospectively assessed prospectively collected nasal swabs using a multiplex assay and compared patients with and without positive results, notably regarding the presence of ARF and ICU mortality.
Methods

Patients
We performed a post hoc analysis of data from a prospective multicenter cohort study of 1,011 critically ill patients with HM admitted to 17 ICUs between January 1, 2010, and May 1, 2011 (14) . The study was approved by the appropriate ethics committees. All patients/relatives gave written informed consent to study participation.
Data Collection
In each center, an investigator used a standardized electronic case-report form to prospectively collect the study data. The Sequential Organ Failure Assessment (SOFA) score was computed at admission. ARF was defined as oxygen saturation ,90% or Pa O 2 less than 60 mm Hg on room air combined with a respiratory rate .30/min and/or clinical signs of respiratory distress (14, 26) . A comprehensive diagnostic assessment was performed including a physical examination and computed tomography followed by bronchoscopy and BAL and/or noninvasive diagnostic tests (2, 11) . Etiologic diagnoses were made by consensus among the managing physicians (intensivists, hematologists, and consultants). Patients with ARF were classified into four diagnostic categories (8): 1) infectious pneumonia as defined by a clinically or microbiologically documented lower respiratory tract infection, 2) noninfectious lung involvement, 3) opportunistic infection, and 4) undetermined diagnosis.
Molecular Assay for Respiratory Virus Detection
Nasopharyngeal flocked swabs were collected at admission in 3 ml of Universal Transport Medium (Copan Diagnostics Inc.) in patients admitted on weekdays and stored at 280 8 C until testing. For the present study, a multiplex molecular assay (ePlex Respiratory Pathogen Panel, GenMark Diagnostics Inc.) was performed according to the manufacturer's instructions. This assay tests for 20 respiratory viruses (influenza viruses A-H1, A-H1N1, A-H3, and B; RSVs A and B; PIV types 1, 2, 3, and 4; hMPV; rhinovirus and/or enterovirus; coronaviruses 229E, HKU1, NL63, OC43, and MERS; adenovirus, and bocavirus) and for four bacteria (Bordetella pertussis, Chlamydophila pneumoniae, Legionella pneumophila, and Mycoplasma pneumoniae).
Samples positive for rhinovirus/enterovirus, underwent
At a Glance Commentary
Scientific Knowledge on the Subject: In critically ill hematology patients, identifying the cause of the acute illness while providing lifesupporting interventions is the cornerstone of the initial management. PCR panels for the rapid detection of viruses are now available. However, the clinical significance of positive PCR results on upper respiratory tract samples remains unclear.
What This Study Adds to the Field: Among critically ill hematology patients, one in six overall and one in four with acute respiratory failure had a virus identified in a nasal swab at ICU admission. Presence of a virus was associated with lymphoproliferative disorders, hematopoietic stem cell transplantation, and treatment with steroids or other immunosuppressants. The most common viruses were rhinovirus/enterovirus (56.4%) and influenza/parainfluenza/respiratory syncytial viruses (30.7%). Virus detection was associated with higher ICU mortality, and this association was strongest for influenza/parainfluenza/ respiratory syncytial viruses. In patients with acute respiratory failure, detection of any respiratory virus independently predicted ICU mortality.
sequencing the VP4/VP2 coding region as previously described (27) . PCR products were sequenced on an ABI 3100 DNA Sequencer (Applied Biosystems, Life Technologies). Alignment and sequence comparison to National Center for Biotechnology Information published sequences were performed using the Geneious 8.0.5 software (Biomatters) and MEGA version 7 (CEMI).
Statistical Analysis
The primary outcome was the rate of respiratory viral infections in patients with ARF and those without. Secondary outcomes were the association between respiratory viral infections and death in ICU and risk factors of death in patients with ARF. Several groups were compared: patients with respiratory viral infections and those without, patients with and without ARF. ePlex-positive status was defined as the detection of at least one pathogen by the ePlex respiratory panel.
Categorical variables were described as numbers and percentages and quantitative variables as medians (interquartile range). Between-group comparisons were with Fisher exact test for categorical variables and the Wilcoxon rank sum test for quantitative variables.
Factors associated with ICU mortality were assessed by logistic regression. In addition to the ePlex assay result, the model included both the variables associated with the outcome in the original study (14) 
Results
Patients
Among the 1,011 critically ill hematology patients, 747 had nasal swabs tested by ePlex ( Figure 1) . None of the collected variables were significantly different between the 747 included patients and the 264 patients without nasal swabs. 
Results of Molecular Viral Detection
The ePlex Respiratory Pathogen Panel identified 179 pathogens in 163 (21.8%) patients, including 149 (83.2%) with a single pathogen and 14 with more than one pathogen (12 with two and two with three pathogens). Four samples were positive for L. pneumophila. All other samples were positive for respiratory viruses ( Table 2) .
The most prevalent virus was rhinovirus/enterovirus (n = 92/163; 56.4%), followed by coronavirus (n = 22; 13.5%), influenza virus (n = 20; 12.3%), RSV (n = 18; 11.0%), and PIV (n = 12; 7.4%). Adenovirus (n = 5; 3.1%), hMPV (n = 4; 2.5%), and bocavirus (n = 2; 1.2%) were less frequently detected. The virus type was determined for 71 of the 92 rhinovirus/enterovirus-positive samples, with the following results: rhinovirus species A, n = 35; rhinovirus species B, n = 9; rhinovirus species C, n = 24; and enterovirus D68, n = 3. Of the respiratory viruses, 66.8% were detected during the winter and spring. There was a seasonal variation of samples positive for respiratory viruses (Table 3 ). Influenza and RSV were significantly more detected during winter (P , 0.0001), whereas rhinoviruses were slightly more frequent during summer and autumn (P = 0.02) (see Table E1 in the online supplement).
Overall, respiratory viruses were more frequently detected in patients with ARF (25.5% vs. 16.3%; P = 0.004) and in patients who died in the ICU (28.9% vs. 19.3%; P = 0.008) ( prevalent in patients with ARF (10.1% vs. 1.7%; P , 0.0001) and in patients who died in the ICU (11.3% vs. 5.1%; P = 0.004). Rhinovirus/enterovirus, coronavirus, adenovirus, hMPV, and bocavirus were found in similar proportions of patients across subgroups with versus without ARF and in ICU survivors versus nonsurvivors. Viral-viral or viral-bacterial coinfections were not associated with ARF but were more prevalent in patients who died in the ICU (5.7 vs. 0.5%; P , 0.0001).
Characteristics and Outcomes of Patients with a Positive Viral Assay
As shown in Table E2 ). In patients with no respiratory symptoms, there was no difference of mortality in ICU between patients with a positive ePlex result and those with a negative ePlex result (see Table E3 ).
Overall there was no difference in of the presence of rhinovirus in patients who died in ICU compared with those who were discharged alive (Table 2 ). However, death was observed more frequently in patients with a detection of rhinovirus species C (11/24; 45.8%) than in those with a detection of rhinovirus species A or B (9/44; in 20.5%) (Fisher exact test; P = 0.049) ( Table 2 ). In addition, within the cohort of patients with ARF (447 patients), we observed a higher proportion of death among patients with rhinovirus species C (9/17; 52.9%) than among patients with rhinovirus species A or B (P = 0.049).
Noninvasive ventilation was used significantly more often in virus-positive patients (39.9% vs. 29.6%; P = 0.017). For invasive mechanical ventilation, the difference was nearly significant (54.0% vs. 45.0%; P = 0.053). ICU mortality was higher in virus-positive patients (34.3% vs. 23.6%; P = 0.008). No significant difference was found for hospital mortality (41.1% vs. 36%; P = 0.27) or mortality on Day 90 (47.7% vs. 45.2%; P = 0.69). There were no differences in the use of vasoactive drugs or renal-replacement therapy or in the rate of ICU-acquired infections (Table 3) .
Characteristics and Outcomes Associated with Respiratory Virus Detection in Patients with ARF
In the group with ARF (Table 4) , the clinical presentation at admission was similar in the virus-positive and virus-negative patients. Although there was no difference in maximal oxygen flow in patients breathing spontaneously, the Pa O 2 /FI O 2 ratio tended to be lower in the virus-positive patients who required mechanical ventilation (118 vs. 150 [96-258]; P = 0.052).
The chest radiograph was more often normal in the virus-positive patients (17.9% vs. 9.9%; P = 0.039). In patients who underwent computed tomography of the chest, the only finding that differed between groups was pleural effusion, which was significantly less common in the viruspositive group (12.3% vs. 24.8%; P = 0.009).
Among virus-positive patients with ARF, 27.2% had clinically or microbiologically documented bacterial pneumonia. Documented bacterial pneumonia was less common among viruspositive than virus-negative patients. IPA was diagnosed in 9.7% of virus-positive and 3.9% of virus-negative patients ( Table 4) .
The use of antibiotics and of lifesupporting interventions (mechanical ventilation, vasoactive drugs, renalreplacement therapy) in the group with ARF Definition of abbreviation: IQR = interquartile range. The data are n (%) unless otherwise specified. *Some patients were admitted for more than one reason.
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was not significantly different between virus-positive and virus-negative patients. As in the overall population, a positive viral assay was associated with higher ICU mortality in the ARF group (40.3% vs. 24.3%; P = 0.002). The hospital and Day 90 mortality rates were not different between the virus-positive and virus-negative groups. Changes in the daily SOFA score from admission to Day 7 were not different between virus-positive and virus-negative patients (see Figure E1 ) and/or patients with versus without detection of influenzalike viruses (see Figure E1) . By multivariable analysis, detection of a virus was independently associated with ICU mortality (OR, 2.07; 95% CI, 1.22-3.50; P = 0.006). Other independent risk factors for ICU mortality were IPA (OR, 2.43; 95% CI, 1.23-4.81; P = 0.01), poor ECOG performance status (OR, 1.89; 95% CI, 1.09-3.27; P = 0.024), and SOFA score greater than seven at admission (OR, 1.27; 95% CI, 1.20-1.36; P , 0.001) (Figure 2 ; see Table E4 ). Steroid therapy was not associated with a worse prognosis in patients with ARF (see Tables E5 and E6 ).
Impact of Influenza-like Viruses
In the overall population, patients with influenza-like viruses had higher ICU mortality (44.4% vs. 24.5%; P = 0.002). They more often presented with ARF (88.9% vs. 57.6%; P , 0.0001) and more often required invasive or noninvasive mechanical ventilation (75.9% vs. 58.7%; P = 0.014) (Figure 3 ).
Discussion
In this study, we assessed the clinical relevance of a positive multiplex PCR assay for viruses on respiratory samples of critically ill hematology patients. We analyzed nasopharyngeal swabs collected at admission to ICU in patients with or without respiratory symptoms, enabling to better estimate the clinical significance of detection of respiratory viruses. In this large multicenter prospective cohort study of 747 critically ill patients with HMs, respiratory virus detection was associated with both ARF and higher ICU mortality. Both associations were largely caused by the influenza-like viruses (influenza/PIV/RSV). Species C of rhinovirus was associated with a higher proportion of death among patients in the whole cohort and in patients with ARF than rhinovirus species A or B.
Although there is no recommendation for routine molecular testing, multiplex PCR is widely used to identify the cause of ARF, in combination with clinical, radiologic, and standard microbiologic evaluations. However, because of the high sensitivity of molecular assays and high prevalence of asymptomatic carriage of respiratory viruses, a positive molecular assay is not proof that the detected virus is causing disease. Immunosuppression may increase the burden of viruses not conventionally associated with significant disease, so that a positive PCR assay may be merely a marker for poor immune function (28) . In addition, presence of a virus can alter the bacterial flora in the upper respiratory tract, an effect that might in turn promote bacterial pneumonia (29) . Finally, respiratory viruses may enhance bacterial adhesion to, and invasion of, the respiratory mucosa (29) . In studies of patients with communityacquired bacterial pneumonia, viral coinfection was associated with a worse prognosis (30) (31) (32) . Thus, the effects of respiratory viruses are complex, and whether virus detection by PCR in an upper airway sample from a critically ill hematology patient should lead to antiviral treatment is unclear.
As a first step toward obtaining clarification, we routinely sampled the upper airway of unselected, critically ill, hematology patients at ICU admission, regardless of whether respiratory symptoms were present. The results were analyzed at a distance from ICU admission. Presence of a virus in this setting might indicate a direct contribution of the virus to the critical illness (e.g., viral pneumonia), an indirect contribution of the virus via alterations in respiratory tract ecology and mucosal function, asymptomatic carriage with no role for the virus in the symptoms but a possible viral load increase because of immunosuppression, or a false-positive test result. Antiviral treatment would be in order only in the first two cases. The lack of lower respiratory tract samples, such as bronchoalveolar lavages, hampered direct evaluation of the impact on respiratory tract ecology and mucosal function. We sought to determine whether any of our findings were in favor of a direct or indirect causal role for detected viruses in the clinical illness.
Half the pathogens detected in our patients were rhinovirus/enterovirus. With coronaviruses, rhinoviruses are the leading cause of rhinitis, and less often cause pneumonia (28, (33) (34) (35) (36) (37) . The higher prevalence of these viruses than previously reported in hematology patients may be because of the very high sensitivity of ePlex, particularly for rhinovirus species C. Several studies have recently shown that rhinovirus could contribute to severe lower respiratory tract infections in immunocompromised hosts (38) (39) (40) . Severe rhinovirus infections presented with similar clinical features and same overall mortality than influenza-like viruses. In our study including patients with or without respiratory symptoms at admission, the prevalence of rhinovirus did not differ, neither between patients with and without ARF, nor between those who died in the ICU and those who were alive at ICU discharge. Rhinovirus is classified into three species (A, B, and C). Some studies reported that species C was associated with more severe infections, with more frequent lower respiratory tract infections (41, 42) but some others found no difference between the three species (40, 43) . In addition, recent studies suggest that species C targets specifically ciliated epithelial cells, whereas species A and B may infect Definition of abbreviations: ARF = acute respiratory failure; IQR = interquartile range; SOFA = Sequential Organ Failure Assessment. Quantitative data are reported as median (IQR) and categorical data as n (%).
nonepithelial cells (44) . The analysis of rhinovirus as one group only may thus be not appropriate. In this series, we found that species C was associated with a higher mortality in the whole cohort and in patients with ARF compared with species A and B. These results suggest that the impact of rhinovirus infection may differ according to the species. This observation needs to be confirmed in other studies and deserves further research to understand underlying mechanisms.
Other viruses were detected in similar proportions of patients after adjustment for age and season. In keeping with this fact, the higher frequencies of ARF and ICU death in the virus-positive group was largely ascribable to the patients with influenza-like Quantitative data are reported as median (IQR) and categorical data as n (%).
viruses (influenza/PIV/RSV, hMPV).
Others have reported similar results (45) . Thus, in agreement with other studies, our results emphasize the need for specific antiviral therapy in critically ill patients with HM when a molecular multiplex assay is positive for influenza in an upper respiratory tract sample. Early oseltamivir therapy improves the outcome in critically ill patients with influenza in a propensity analysis (46) (47) (48) .
Among patients with ARF, respiratory virus detection was a predictor of ICU mortality that was nearly as strong as IPA. Although IPA is a well-known risk factor for mortality in critically ill hematology patients, our study is the first to report that respiratory viruses were also independently associated with ICU mortality. Three hypotheses may explain this association. One involves a double hit, in which patients developing a respiratory virus infection shortly before ICU admission would be then more vulnerable to bacterial infection, leading to a critical illness. The lower Pa O 2 /FI O 2 ratio in virus-positive patients may seem to support this possibility, but the more often normal chest radiographs and similar SOFA scores over the first week compared with virus-negative patients do not. Another hypothesis is that bacterial or fungal respiratory tract infection would promote viral infection via weakening of the local defense mechanisms (49) . The viral infection may then worsen the initial disease. A recent work suggested that the alteration of microbial ecology after antibiotic exposure was associated with a higher risk of viral lower respiratory tract infection with following PIV, RSV, and hMPV (50) . Viral infections and invasive fungal infections share common risk factors (51-53) that are common in hematology patients, such as allogeneic HSCT and treatment with corticosteroids or other immunosuppressants. Finally, a positive viral assay might be a marker for immunosuppression or other vulnerability factors.
The contribution of PCR assays to the etiologic diagnosis of ARF is probably modest. Nevertheless, our results suggest that rapid routine multiplex molecular testing for upper respiratory tract viruses in hematology patients admitted to the ICU may contribute to identify patients at highest risk for mortality. Such finding could be delineated into different ways. Namely, based on a positive virus in the nasal swab, these highrisk patients should be admitted earlier to the ICU to undergo noninvasive management and close monitoring. Moreover, these patients should be considered as more severely immunocompromised and may also be eligible for preventive strategies, such as antifungal prophylaxis. However, for such practices to be implemented, these concepts need to be validated in future observational and interventional studies. Although antiviral drugs available to treat respiratory viral infections are currently limited to influenza, our results identify patients who should benefit from new antiviral drugs or be included in trials evaluating treatments under development.
Regarding the association with IPA, antifungal treatment might be in order in patients with ARF who do not respond promptly to antibacterial treatment and whose multiplex test for upper respiratory tract viruses is positive. In patients whose test is positive for influenza, early antiviral treatment and preventive measures to limit nosocomial transmission may be warranted. Our results suggest that critically ill hematology patients may be a population of interest for evaluating new drugs targeting RSV and PIV.
This study has several limitations. For feasibility reasons, 264 patients (26.1% of the initial cohort) admitted on weekends were not included. However, the baseline characteristics and ICU mortality of these 264 patients were not significantly different from those in the included patients. We had no information on the occurrence of hospital-acquired pneumonia or ventilatorassociated pneumonia during the ICU stay. The study design does not allow conclusions about the nature of the link between the detection of viruses and ICU mortality. Indeed, although mortality related to infection is usually high in this setting, ascription of death to infection was not assessed because of the level of uncertainty. Future studies involving the collection of biomarkers and specific patient phenotypes in this hematology population are warranted. Also, lower respiratory tract samples and autopsy studies of the lung lesions might shed light on the role for viruses versus other causes of lung involvement, document undetected pathogens, and provide information on resident and recruited alveolar cells and their relationship to severity and mortality.
In conclusion, a respiratory virus was detected in the upper airway of one in six critically ill hematology patients overall and of one in four of those with ARF. Virus detection was more common in patients who died in the ICU, and this association was chiefly caused by influenza/PIV/RSV. In patients with ARF, however, detection of any respiratory virus was an independent predictor of ICU mortality. Routine PCR screening of upper airway samples in critically ill hematology patients may help to identify patients at high risk for respiratory deterioration and mortality. However, whether these patients are potential candidates for immunomodulation, new antiviral treatments, early ICU admission, or antifungal therapy remains unclear. These results encourage a trial of routine screening for respiratory viral detection by PCR at ICU admission in hematology patients. Therapeutic indications must be appraised. This high-risk population may be a good target for evaluating the antiviral treatments that are currently being developed. n Author disclosures are available with the text of this article at www.atsjournals.org.
